BABA vs NCI

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

Despite a strong Piotroski F-Score of 7/9 and extreme valuation discounts (Graham Number $3.39 vs Price $0.51), NCI exhibits the classic characteristics of a value trap. The company is experiencing a catastrophic price collapse, with a 91.8% decline in the last month and a 98.9% loss over five years. While earnings are growing and ROE is positive, the 24% YoY revenue contraction and total lack of technical momentum suggest a fundamental breakdown in market confidence that outweighs the deterministic value metrics.